MCID: MYL006
MIFTS: 64

Myeloid Leukemia malady

Genetic diseases, Rare diseases, Cancer diseases, Immune diseases, Blood diseases categories

Aliases & Classifications for Myeloid Leukemia

About this section

Aliases & Descriptions for Myeloid Leukemia:

Name: Myeloid Leukemia 8 42 44 61
Myeloid Leukemia in Remission 8 61
Leukemia, Myeloid 42 22
Unspecified Myeloid Leukemia Without Mention of Remission 8
Other Myeloid Leukemia Without Mention of Remission 8
Myeloid Leukemia, Nos, Without Mention of Remission 8
Unspecified Myeloid Leukemia in Remission 8
Other Myeloid Leukemia, in Remission 61
Other Myeloid Leukemia in Remission 8
Myeloid Leukemia, No Icd-O Subtype 8
 
Myelogenous Leukemia in Remission 8
Myeloid Granulocytic Leukemia 8
Other Myeloid Leukemia Nos 8
Myeloid Leukemia, Disease 8
Non-Lymphocytic Leukemia 8
Other Myeloid Leukemia 8
Leukemia Myelogenous 8
Myeloid Leukemia Nos 8
Myeloid Leukaemia 8
Myeloid Leukemias 8


Classifications:



External Ids:

Disease Ontology8 DOID:8692
NCIt39 C3172
ICD9CM27 205, 205.9
ICD1025 C92, C92.7

Summaries for Myeloid Leukemia

About this section
Wikipedia:64 Myeloid leukemia is a type of leukemia affecting myeloid tissue. more...

MalaCards based summary: Myeloid Leukemia, also known as myeloid leukemia in remission, is related to leukemia and myelodysplastic syndrome. An important gene associated with Myeloid Leukemia is PICALM (phosphatidylinositol binding clathrin assembly protein), and among its related pathways are Notch Signaling Pathways and TGF-beta Signaling Pathways. The compounds gp 130 and ponatinib have been mentioned in the context of this disorder. Affiliated tissues include myeloid tissue, myeloid and bone, and related mouse phenotypes are tumorigenesis and craniofacial.

Disease Ontology:8 A leukemia that is located in myeloid tissue.

Related Diseases for Myeloid Leukemia

About this section

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia, Adult
Npm1-Related Acute Myeloid Leukemia Inherited Acute Myeloid Leukemia
'acute Myeloid Leukemia with T(9;11)(p22;q23)' 'acute Myeloid Leukemia with T(6;9)(p23;q34)'

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 431)
idRelated DiseaseScoreTop Affiliating Genes
1leukemia32.2RUNX3, RUNX1, RUNX1T1, RUNX2, ABL1, NPM1
2myelodysplastic syndrome32.0RUNX1, ABL1, MLF1, PTPN11, FLT3, CBFB
3chronic myelomonocytic leukemia31.6RUNX1, PTPN11, FLT3
4wilms tumor31.5ABL1, FLT3, CREBBP
5acute myeloid leukemia, adult31.5RUNX1, PTPN11, FLT3, NPM1
6leukemia, acute myeloid31.4RUNX1, MLF1, FLT3, CEBPA, NPM1
7refractory anemia31.4FLT3, RUNX1
8leukemia, chronic myeloid31.4RUNX1, ABL1, PTPN11, FLT3, CBFB, CREBBP
9down syndrome31.2RUNX1, FLT3, ERG
10acute leukemia31.1MLF1, PTPN11, FLT3, CBFB, CEBPA, CREBBP
11leukemia, acute promyelocytic31.1RUNX1, RUNX1T1, FLT3, CREBBP, NPM1
12gastrointestinal stromal tumor31.0MYH11, FLT3, ABL1
13acute myelomonocytic leukemia31.0RUNX1, CBFB, CREBBP
14monocytic leukemia31.0LIF, RUNX1
15breast cancer30.8RUNX3, RUNX1, RUNX2, ABL1, PTPN11, FLT3
16colorectal cancer30.7CREBBP, PTPN11, ABL1, RUNX1, RUNX3
17cleidocranial dysplasia30.6RUNX3, RUNX1, RUNX2, CBFB
18precursor t-cell acute lymphoblastic leukemia30.6FLT3, PICALM, ABL1, RUNX1
19retinoblastoma30.4NPM1, CREBBP, CEBPA, ABL1, RUNX2, RUNX1
20leukemia, acute lymphoblastic30.3RUNX1, ABL1, PICALM, PTPN11, FLT3, CBFB
21hematologic cancer30.3RUNX1, RUNX1T1, ABL1, PICALM, PTPN11, FLT3
22cytogenetically normal acute myeloid leukemia11.0
23core binding factor acute myeloid leukemia10.9
24sarcoma10.9
25myeloid sarcoma10.8
26hematopoietic stem cell transplantation10.8
27lymphoblastic leukemia10.7
28endotheliitis10.7
29neutropenia10.7
30mastocytosis10.6
31systemic mastocytosis10.6
32familial acute myeloid leukemia with mutated cebpa10.6
33acute myeloid leukemia with multilineage dysplasia10.6
34myelofibrosis10.6
35subacute myeloid leukemia10.6
36thrombocytosis10.5
37diphtheria10.5
38essential thrombocythemia10.5
39philadelphia-negative chronic myeloid leukemia10.5
40tetraploidy10.5
41aspergillosis10.5
42diabetes insipidus10.5
43mediastinitis10.5
44polycythemia10.5
45aplastic anemia10.5
46multiple myeloma10.5
47chronic lymphocytic leukemia10.5
48thrombocytopenia10.5
49eosinophilia10.5
50myeloma10.5

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to myeloid leukemia

Symptoms for Myeloid Leukemia

About this section

Drugs & Therapeutics for Myeloid Leukemia

About this section

FDA approved drugs:

(show all 7)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Bosulif13 38 BOSUTINIB MONOHYDRATE Pfizer Approved September 2012
FDA Label: Bosulif
Malady that Drug Treats: Ph+ chronic myelogenous leukemia
Indications and Usage:13 BOSULIF is a kinase inhibitor indicated for the treatment of adult patients; with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia; (CML) with resistance or intolerance to prior therapy. (1)
DrugBank Targets:11 1. Breakpoint cluster region protein; 2. Tyrosine-protein kinase ABL1; 3. Tyrosine-protein kinase Lyn; 4. Tyrosine-protein kinase HCK; 5. Proto-oncogene tyrosine-protein kinase Src; 6. Cyclin-dependent kinase 2; 7. Dual specificity mitogen-activated protein kinase kinase 1; 8. Dual specificity mitogen-activated protein kinase kinase 2; 9. Mitogen-activated protein kinase kinase kinase 2; 10. Calcium/calmodulin-dependent protein kinase type II subunit gamma
Mechanism of Action:13 
Target: tyrosine kinase/ Src-family kinases including Src, Lyn, and Hck
Action: inhibitor
FDA: Bosutinib is a tyrosine kinase inhibitor. Bosutinib inhibits the Bcr-Abl kinase that promotes CML; it is also an; inhibitor of Src-family kinases including Src, Lyn, and Hck. Bosutinib inhibited 16 of 18 imatinib-resistant forms of; Bcr-Abl expressed in murine myeloid cell lines. Bosutinib did not inhibit the T315I and V299L mutant cells. In mice,; treatment with bosutinib reduced the size of CML tumors relative to controls and inhibited growth of murine myeloid; tumors expressing several imatinib-resistant forms of Bcr-Abl.
2
Gleevec13 38 IMATINIB MESYLATE Novartis Approved May 2001
FDA Label: Gleevec
Malady that Drug Treats: chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs)
Indications and Usage:13 Gleevec"! (imatinib mesylate) is indicated for the treatment of newly diagnosed adult; patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic; phase. Follow-up is limited. ; Page 10; Gleevec is also indicated for the treatment of patients with Philadelphia chromosome; positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic; phase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment of; pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell; transplant or who are resistant to interferon alpha therapy. There are no controlled trials; demonstrating a clinical benefit, such as improvement in disease-related symptoms or; increased survival.; Gleevec is also indicated for the treatment of patients with Kit (CD117) positive; unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (See; CLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec in; GIST is based on objective response rate (see CLINICAL STUDIES). There are no controlled; trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or; increased survival.
DrugBank Targets:11 1. BCR/ABL fusion protein isoform X9; 2. Mast/stem cell growth factor receptor Kit; 3. RET proto-oncogene; 4. High affinity nerve growth factor receptor; 5. Macrophage colony-stimulating factor 1 receptor; 6. Platelet-derived growth factor receptor alpha; 7. Epithelial discoidin domain-containing receptor 1; 8. Tyrosine-protein kinase ABL1; 9. Platelet-derived growth factor receptor beta
Mechanism of Action:13 
Target: protein-tyrosine kinase
Action: inhibitor
FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine; kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome; abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces; apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia; chromosome positive chronic myeloid leukemia. In colony formation assays using ex vivo; peripheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positive; colonies from CML patients.; In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as well; as Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.; Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived; growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and; SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in; gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
3
Iclusig13 38 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals Approved December 2012
FDA Label: Iclusig
Malady that Drug Treats: chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia
Indications and Usage:13 Iclusig is a kinase inhibitor indicated for the:; Treatment of adult patients with T315I-positive chronic myeloid; leukemia (chronic phase, accelerated phase, or blast phase) or T315Ipositive; Philadelphia chromosome positive acute lymphoblastic; leukemia (Ph+ ALL).; Treatment of adult patients with chronic phase, accelerated phase, or; blast phase chronic myeloid leukemia or Ph+ ALL for whom no other; tyrosine kinase inhibitor (TKI) therapy is indicated. (1); These indications are based upon response rate. There are no trials verifying an; improvement in disease-related symptoms or increased survival with Iclusig.
DrugBank Targets:11 1. Tyrosine-protein kinase ABL1; 2. Breakpoint cluster region protein; 3. Mast/stem cell growth factor receptor Kit; 4. Proto-oncogene tyrosine-protein kinase receptor Ret; 5. Angiopoietin-1 receptor; 6. Receptor-type tyrosine-protein kinase FLT3; 7. Fibroblast growth factor receptor 1; 8. Fibroblast growth factor receptor 2; 9. Fibroblast growth factor receptor 3; 10. Fibroblast growth factor receptor 4; 11. Tyrosine-protein kinase Lck; 12. Proto-oncogene tyrosine-protein kinase Src; 13. Tyrosine-protein kinase Lyn; 14. Vascular endothelial growth factor receptor 2; 15. Platelet-derived growth factor receptor alpha
Mechanism of Action:13 
Target: tyrosine kinase activity of ABL and T315I mutant ABL
Action: inhibitor
FDA: Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with; IC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50; concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC; families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native or; mutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native or; T315I mutant BCR-ABL when compared to controls.
4
Mylotarg13 38 GEMTUZUMAB OZOGAMICIN Wyeth Approved May 2000
FDA Label: Mylotarg
Malady that Drug Treats: Acute Myeloid Leukemia (AML)
Indications and Usage:13 Mylotarg is indicated for the treatment of patients with CD33 positive acute myeloid leukemia in; first relapse who are 60 years of age or older and who are not considered candidates for other; cytotoxic chemotherapy. The safety and efficacy of Mylotarg in patients with poor performance; status and organ dysfunction has not been established.; The effectiveness of Mylotarg is based on OR rates (see CLINICAL STUDIES section). There; are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related; symptoms or increased survival, compared to any other treatment.
DrugBank Targets:11 1. Myeloid cell surface antigen CD33; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. Complement C1s subcomponent; 9. High affinity immunoglobulin gamma Fc receptor I; 10. Low affinity immunoglobulin gamma Fc region receptor II-a; 11. Low affinity immunoglobulin gamma Fc region receptor II-b; 12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: CD33 antigen expressed by; hematopoietic cells
Action: binds to form complex that then causes a break in the DNA double strand
FDA: Mylotarg is directed against the CD33 antigen expressed by; hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33; antigen results in the formation of a complex that is internalized. Upon internalization, the; calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released; calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand; breaks and cell death.; Gemtuzumab ozogamicin is cytotoxic to the CD33 positive HL-60 human leukemia cell line.; Gemtuzumab ozogamicin produces significant inhibition of colony formation in cultures of adult; leukemic bone marrow cells. The cytotoxic effect on normal myeloid precursors leads to; substantial myelosuppression, but this is reversible because pluripotent hematopoietic stem cells; are spared. In preclinical animal studies, gemtuzumab ozogamicin demonstrates antitumor; effects in the HL-60 human promyelocytic leukemia xenograft tumor in athymic mice.
5
Sprycel13 38 DASATINIB Bristol-Myers Squibb Approved June 2006
FDA Label: Sprycel
Malady that Drug Treats: Chronic Myeloid Leukemia
Indications and Usage:13 SPRYCEL is a kinase inhibitor indicated for the treatment of; newly diagnosed adults with Philadelphia chromosome-positive (Ph+); chronic myeloid leukemia (CML) in chronic phase. (1, 14); adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+; CML with resistance or intolerance to prior therapy including imatinib. (1,; 14); adults with Philadelphia chromosome-positive acute lymphoblastic; leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14)
DrugBank Targets:11 1. Tyrosine-protein kinase ABL1; 2. Proto-oncogene tyrosine-protein kinase Src; 3. Ephrin type-A receptor 2; 4. Tyrosine-protein kinase Lck; 5. Tyrosine-protein kinase Yes; 6. Mast/stem cell growth factor receptor Kit; 7. Platelet-derived growth factor receptor beta; 8. Signal transducer and activator of transcription 5B; 9. Abelson tyrosine-protein kinase 2; 10. Tyrosine-protein kinase Fyn
Mechanism of Action:13 
Target: BCR-ABL, SRC family; (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR² kinases
Action: inhibitor
FDA: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family; (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR². Based on modeling studies, dasatinib is; predicted to bind to multiple conformations of the ABL kinase.; In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate; sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia; (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the; conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABL; kinase domain mutations, activation of alternate signaling pathways involving the SRC; family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
6
Synribo13 38 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical Approved October 2012
FDA Label: Synribo
Malady that Drug Treats: chronic or accelerated phase chronic myeloid leukemia
Indications and Usage:13 SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI) (1)
DrugBank Targets:11 1. 50S ribosomal protein L2; 2. 60S ribosomal protein L3
Mechanism of Action:13 
Target: A-site cleft in the peptidyl-transferase center of the; large ribosomal subunit from a strain of archaeabacteria
Action: inhibitor of protein synthesis
FDA: The mechanism of action of omacetaxine mepesuccinate has not been fully elucidated but includes inhibition of protein synthesis and; is independent of direct Bcr-Abl binding. Omacetaxine mepesuccinate binds to the A-site cleft in the peptidyl-transferase center of the; large ribosomal subunit from a strain of archaeabacteria. In vitro, omacetaxine mepesuccinate reduced protein levels of the Bcr-Abl; oncoprotein and Mcl-1, an anti-apoptotic Bcl-2 family member. Omacetaxine mepesuccinate showed activity in mouse models of; wild-type and T315I mutated Bcr-Abl CML.
7
Tasigna13 38 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis Approved October 2007
FDA Label: Tasigna
Malady that Drug Treats: chronic myelogenous leukemia
Indications and Usage:13 Tasigna is a kinase inhibitor indicated for:; The treatment of newly diagnosed adult patients with Philadelphia; chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.; The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML in; adult patients resistant to or intolerant to prior therapy that included imatinib.; (1.2); --------------
DrugBank Targets:11 1. Tyrosine-protein kinase ABL1; 2. Mast/stem cell growth factor receptor Kit
Mechanism of Action:13 
Target: Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF)
Action: inhibitor of signal transduction
FDA: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of; the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine; leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the; assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out; of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.; Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20; to 60 nM), PDGFR (69 nM), c-KIT (210 nM), CSF-1R (125 to 250 nM), and DDR1 (3.7 nM).

Drug clinical trials:

Search ClinicalTrials for Myeloid Leukemia

Search NIH Clinical Center for Myeloid Leukemia

Genetic Tests for Myeloid Leukemia

About this section

Genetic tests related to Myeloid Leukemia:

id Genetic test Affiliating Genes
1 Myeloid Leukemia22

Anatomical Context for Myeloid Leukemia

About this section

MalaCards organs/tissues related to Myeloid Leukemia:

31
Myeloid, Bone, Bone marrow, T cells, Monocytes, Endothelial, B cells, Neutrophil, Breast, Lung, Testis, Nk cells, Colon, Testes, Skin, Kidney, Lymph node, Brain, Liver, Thyroid, Eye, Spleen, Thymus, Heart, Smooth muscle, Pancreas, Placenta, Prostate, Tonsil, B lymphoblasts, Pituitary

FMA organs/tissues related to Myeloid Leukemia:

14
Myeloid tissue

Animal Models for Myeloid Leukemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Myeloid Leukemia:

35 (show all 22)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.8CEBPA, NPM1, CBFB, CREBBP, FLT3, PTPN11
2MP:00053829.8ABL1, PTPN11, CREBBP, RUNX2, CBFB
3MP:00030129.7RUNX3, RUNX1, RUNX2, PTPN11, CBFB, CEBPA
4MP:00053759.7LIF, CREBBP, CEBPA, PTPN11, RUNX3
5MP:00053919.6CBFB, NPM1, CEBPA, LIF, PTPN11, ABL1
6MP:00053909.6CBFB, LIF, PTPN11, CREBBP, ABL1, RUNX1
7MP:00053709.5LIF, ABL1, RUNX2, CBFB, NPM1, CEBPA
8MP:00028739.5ERG, RUNX1, RUNX1T1, ABL1, PTPN11, CEBPA
9MP:00053809.4LIF, ABL1, NPM1, ERG, CREBBP, CBFB
10MP:00053889.4PTPN11, MYH11, LIF, CBFB, CREBBP, RUNX1
11MP:00053799.4CREBBP, CEBPA, LIF, PTPN11, RUNX2, RUNX3
12MP:00053699.4PTPN11, RUNX3, MYH11, CEBPA, RUNX2, ABL1
13MP:00107719.3RUNX1T1, RUNX2, PTPN11, NPM1, LIF, CBFB
14MP:00036319.2PTPN11, LIF, CBFB, CREBBP, ERG, NPM1
15MP:00053819.2LIF, MYH11, RUNX1T1, CREBBP, CEBPA, CBFB
16MP:00053769.2CBFB, CEBPA, CREBBP, RUNX2, LIF, MYH11
17MP:00053849.2NPM1, CREBBP, FLT3, RUNX3, RUNX1, RUNX2
18MP:00053979.0RUNX3, RUNX1, RUNX2, ABL1, PTPN11, FLT3
19MP:00053879.0NPM1, CREBBP, ERG, LIF, CBFB, ABL1
20MP:00053858.9CBFB, CREBBP, ERG, NPM1, LIF, MYH11
21MP:00053788.8PICALM, CEBPA, MYH11, LIF, CBFB, CREBBP
22MP:00107688.6RUNX1T1, RUNX1, RUNX3, PTPN11, RUNX2, ABL1

Publications for Myeloid Leukemia

About this section

Articles related to Myeloid Leukemia:

(show top 50)    (show all 4848)
idTitleAuthorsYear
1
Crucial role of heme oxygenase-1 in the sensitivity of acute myeloid leukemia cell line Kasumi-1 to ursolic acid. (24413389)
2014
2
A case of therapy-related acute myeloid leukemia with a normal karyotype after sustained molecular complete remission of acute promyelocytic leukemia. (24422201)
2014
3
Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. (24120526)
2014
4
Intraventricular hemorrhage in a patient with chronic myeloid leukemia and anterior communicating artery aneurysm. (23860156)
2013
5
Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. (24035334)
2013
6
Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. (23553655)
2013
7
Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. (23912609)
2013
8
Sudden extramedullary blast crisis of chronic myeloid leukemia manifesting as T-cell lymphoblastic lymphoma. (23486000)
2013
9
Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia. (24179607)
2013
10
Dasatinib: a guide to its use in chronic myeloid leukemia in the EU. (23549840)
2013
11
Prognostic implication of BAALC gene expression in adult acute myeloid leukemia. (23865362)
2013
12
CAR T cells for acute myeloid leukemia: the LeY of the land. (24201214)
2013
13
Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells. (23878608)
2013
14
Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting. (22929312)
2012
15
Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. (21692072)
2012
16
The high Nrf2 expression in human acute myeloid leukemia is driven by NF-I_B and underlies its chemo-resistance. (23077289)
2012
17
High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. (22915059)
2012
18
Synergistic effect of 5-azacytidine and NF-I_B inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells. (24139415)
2012
19
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. (22490330)
2012
20
DNMT3A mutations are rare in childhood acute myeloid leukemia. (21685466)
2011
21
Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms. (21951951)
2011
22
Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006. (20199658)
2010
23
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. (21156465)
2010
24
Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. (19637342)
2009
25
An unusual case of febrile neutropenia: acute myeloid leukemia presenting as myeloid sarcoma of the spleen. (18717148)
2008
26
Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. (18768433)
2008
27
Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. (18616510)
2008
28
Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. (18268283)
2008
29
Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. (18401414)
2008
30
Analysis of NPM1 gene mutations in acute myeloid leukemia]. (17877154)
2007
31
Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia. (17822317)
2007
32
Induction of G2/M phase arrest and apoptosis by a novel enediyne derivative, THDB, in chronic myeloid leukemia (HL-60) cells. (17064874)
2007
33
Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia. (16923575)
2006
34
Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells. (15744347)
2005
35
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. (15840695)
2005
36
Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. (15034867)
2004
37
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. (12393722)
2003
38
Acute myeloid leukemia associated with necrotizing temporal arteritis. (12672210)
2003
39
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. (12006512)
2002
40
Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML. (11986951)
2002
41
BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. (12145683)
2002
42
Drug therapy of chronic myeloid leukemia]. (11831070)
2002
43
Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. (11587212)
2001
44
Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. (11568008)
2001
45
Cytokine expression of T cells in chronic myeloid leukemia. (11775253)
2000
46
Induction of gp130 and LIF by differentiation inducers in human myeloid leukemia K562 cells. (10613356)
1999
47
In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. (9815618)
1997
48
Rearrangements and fusion gene of AML1 and MTG8 in acute myeloid leukemia M2b]. (7553157)
1995
49
Regulation of the expression of vimentin gene during the differentiation of mouse myeloid leukemia cells. (1970825)
1990
50
"Coexistent chronic myeloid leukemia and lymphosarcoma in the maxilla: report of a case". (6594459)
1984

Variations for Myeloid Leukemia

About this section

Expression for genes affiliated with Myeloid Leukemia

About this section
Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for genes affiliated with Myeloid Leukemia

About this section

Compounds for genes affiliated with Myeloid Leukemia

About this section

Compounds related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 28)
idCompoundScoreTop Affiliating Genes
1gp 1304410.3LIF, FLT3, PTPN11
2ponatinib50 1111.3ABL1, FLT3
3tgf beta14410.3LIF, FLT3, RUNX2
4agarose4410.3NPM1, FLT3, LIF
5cytarabine44 50 1112.3ABL1, LIF, FLT3
6etoposide44 50 60 1113.3PTPN11, RUNX1, CREBBP, FLT3
7imatinib44 50 1112.2RUNX1, FLT3, ABL1, PTPN11
8doxorubicin44 50 1112.2FLT3, NPM1, CREBBP, RUNX1
9herbimycin a44 6011.2FLT3, PTPN11, ABL1
10fatty acid4410.1CREBBP, LIF, CEBPA, NPM1, RUNX2
11proline4410.1CREBBP, PTPN11, ABL1, RUNX1T1, RUNX1
12thymidine44 2411.1PTPN11, RUNX2, LIF, FLT3
13nitric oxide44 24 1112.0LIF, MYH11, PTPN11, RUNX2, CREBBP
14zinc44 2411.0NPM1, CREBBP, ABL1, RUNX2, RUNX1, RUNX1T1
15cisplatin44 50 60 1112.9ABL1, PTPN11, CREBBP, LIF
16atp44 2810.9NPM1, CREBBP, LIF, FLT3, PTPN11, ABL1
17threonine449.9PTPN11, RUNX1, NPM1, CREBBP, FLT3, ABL1
18phosphatidylinositol449.8CREBBP, LIF, RUNX2, ABL1, PTPN11, FLT3
19estrogen449.8NPM1, ABL1, MYH11, LIF, CEBPA, RUNX2
20glucose449.8CEBPA, RUNX2, CREBBP, LIF, PTPN11
21oligonucleotide449.8FLT3, LIF, RUNX3, PTPN11, ABL1, RUNX2
22oxygen44 2410.7ABL1, CREBBP, PTPN11, RUNX2, LIF
23vegf449.6RUNX2, RUNX3, RUNX1, ABL1, PTPN11, FLT3
24serine449.6RUNX1T1, RUNX2, ABL1, PTPN11, MYH11, LIF
25tyrosine449.6PTPN11, ABL1, RUNX2, RUNX1, PCM1, LIF
26retinoic acid44 2410.5ABL1, RUNX3, RUNX1, RUNX2, FLT3, MYH11
27cysteine449.4PTPN11, NPM1, CREBBP, LIF, ABL1
28calcium44 50 24 1112.3NPM1, PTPN11, CREBBP, LIF, MRVI1, RUNX2

GO Terms for genes affiliated with Myeloid Leukemia

About this section

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nuclear chromatinGO:000079010.1CREBBP, RUNX2, RUNX3
2nucleusGO:00056348.5NPM1, RUNX3, RUNX1, RUNX2, ABL1, PICALM
3cytoplasmGO:00057378.3MLF2, MLF1, ABL1, RUNX2, RUNX3, PTPN11

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1peripheral nervous system neuron developmentGO:004893510.4RUNX3, RUNX1
2myeloid cell differentiationGO:003009910.3RUNX1, CBFB, CEBPA
3myeloid progenitor cell differentiationGO:000231810.3FLT3, MLF1, RUNX1
4hemopoiesisGO:003009710.3FLT3, PICALM, RUNX1
5definitive hemopoiesisGO:006021610.3CBFB, RUNX1
6hair follicle morphogenesisGO:003106910.3RUNX1, RUNX3
7cell maturationGO:004846910.2CEBPA, CBFB, RUNX2, RUNX3
8regulation of endocytosisGO:003010010.1PICALM, ABL1
9axon guidanceGO:000741110.0MYH11, PTPN11, ABL1, RUNX3
10transcription from RNA polymerase II promoterGO:000636610.0RUNX3, LIF, CBFB, CEBPA, ERG
11negative regulation of cell proliferationGO:00082859.9FLT3, LIF, CEBPA, NPM1
12positive regulation of transcription, DNA-templatedGO:00458939.7RUNX1, RUNX2, PICALM, CREBBP

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1repressing transcription factor bindingGO:007049110.3RUNX2, RUNX1
2protein homodimerization activityGO:00428039.9RUNX1, RUNX1T1, FLT3, CEBPA, NPM1
3protein domain specific bindingGO:00199049.7PTPN11, MLF1, RUNX2
4sequence-specific DNA binding transcription factor activityGO:00037009.7RUNX3, RUNX1, RUNX1T1, RUNX2, CBFB, CEBPA
5ATP bindingGO:00055249.6RUNX3, RUNX1, RUNX2, ABL1, FLT3, MYH11
6DNA bindingGO:00036779.5RUNX1, RUNX1T1, ABL1, MLF1, CBFB, CEBPA
7protein bindingGO:00055158.2NPM1, RUNX3, RUNX1, RUNX1T1, RUNX2, ABL1

Sources for Myeloid Leukemia

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet